EUVIMEDEUVIMED entdecken
LeserbriefKommentar

It is time for a rethink about caffeine therapy for apnoea of prematurity

Raj Prakash iD

Acta Paediatrica · 2023

DOI: 10.1111/apa.16673 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Acta Paediatrica, 2023. Verfasst von Raj Prakash. Beteiligte Einrichtung: Department of Paediatrics, York Teaching Hospital, York, UK. Hauptthemen laut MEDLINE: Infant, Newborn, Diseases, Infant, Premature, Diseases, Central Nervous System Stimulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It was very interesting to read the national survey on caffeine use in UK neonatal intensive care units (NICUs) by Grainge et al.1 The landmark Caffeine for Apnoea of Prematurity (CAP) trial was originally conducted to resolve the longstanding uncertainty about the safety of using caffeine for preterm infants.2 Caffeine is a competitive inhibitor of adenosine receptors in preterm brains, which stimulates the respiratory centre. In contrast, adenosine is a major neurotransmitter that preserves brain adenosine triphosphate and protects brain cells from hypoxia and ischaemia in experimental animal models.3 A decade after the original CAP trial, concerns about using an adenosine receptor antagonist to treat apnoea of prematurity remain relevant. The CAP trial outcomes at 18 months and five and 11 years would have made many clinicians use caffeine routinely for all preterm infants as a brain or lung drug.2 However, it is often forgotten that this longterm beneficial outcome is mainly achieved by decreasing the duration of positive pressure ventilation, which reduces the noxious effects of mechanical ventilation in the preterm brain and lung. This suggests that caffeine, like any other drug, should be used for a minimum duration to maximise the overall benefit. The Grainge et al survey reported wide UK variations in caffeine therapy1 and the global situation is similar, with no definite recommendations about when to start or stop caffeine. Starting caffeine before day three of life is arbitrarily based on a subgroup analysis of the CAP trial, not highquality randomised controlled trials.2 The published survey found that 71 units (77%) would continue caffeine while babies were mechanically ventilated. But what is the additional advantage of continuing caffeine in a ventilated baby? The same misconception that caffeine can be used as a brain or lung drug? In 2014, a prospective randomised trial of 95 preterm infants in 16 American NICUs by Rhein et al reported decreased intermittent hypoxia when caffeine was extended until 40 weeks.4 We carried out a prospective randomised controlled trial in a tertiary NICU in South India. The 120 preterm infants comprised a longduration group that received caffeine for up to 34 weeks of gestation and a shortduration group, where caffeine was stopped when they had been free of apnoea for 7 days and were off positive pressure ventilation. Continuing caffeine for up to 34 weeks seemed nonbeneficial.5 The benefits of caffeine can be maximised with minimal risks if it is only used for extremely preterm infants on noninvasive respiratory support to prevent apnoea and mechanical ventilation. If preterm babies are already on mechanical ventilation, caffeine can be provided as a periextubation strategy. The best approach for more mature preterm infants may be observation and only starting caffeine if they develop apnoea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Infant, Newborn, DiseasesInfant, Premature, DiseasesCentral Nervous System StimulantsInfant, NewbornHumansCaffeineApneaInfant, Premature

Substanzen

CaffeineCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Department of Paediatrics, York Teaching Hospital, York, UK.

ORCID-Profile: Raj Prakash

Zitieren

APA

Prakash, R. (2023). It is time for a rethink about caffeine therapy for apnoea of prematurity. Acta Paediatrica. https://doi.org/10.1111/apa.16673

Vancouver

Prakash R. It is time for a rethink about caffeine therapy for apnoea of prematurity. Acta Paediatrica. 2023. doi:10.1111/apa.16673

BibTeX
@article{Prakash2023,
  author = {Prakash, Raj},
  title = {It is time for a rethink about caffeine therapy for apnoea of prematurity},
  journal = {Acta Paediatrica},
  year = {2023},
  doi = {10.1111/apa.16673}
}
Kostenlos starten →